van Veenendaal Haske, Peters Loes J, Ubbink Dirk T, Stubenrouch Fabienne E, Stiggelbout Anne M, Brand Paul Lp, Vreugdenhil Gerard, Hilders Carina Gjm
Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
Dutch Association of Oncology Patient Organizations, Utrecht, Netherlands.
JMIR Res Protoc. 2022 Apr 6;11(4):e35543. doi: 10.2196/35543.
Shared decision-making (SDM) is particularly important in oncology as many treatments involve serious side effects, and treatment decisions involve a trade-off between benefits and risks. However, the implementation of SDM in oncology care is challenging, and clinicians state that it is difficult to apply SDM in their actual workplace. Training clinicians is known to be an effective means of improving SDM but is considered time consuming.
This study aims to address the effectiveness of an individual SDM training program using the concept of deliberate practice.
This multicenter, single-blinded randomized clinical trial will be performed at 12 Dutch hospitals. Clinicians involved in decisions with oncology patients will be invited to participate in the study and allocated to the control or intervention group. All clinicians will record 3 decision-making processes with 3 different oncology patients. Clinicians in the intervention group will receive the following SDM intervention: completing e-learning, reflecting on feedback reports, performing a self-assessment and defining 1 to 3 personal learning questions, and participating in face-to-face coaching. Clinicians in the control group will not receive the SDM intervention until the end of the study. The primary outcome will be the extent to which clinicians involve their patients in the decision-making process, as scored using the Observing Patient Involvement-5 instrument. As secondary outcomes, patients will rate their perceived involvement in decision-making, and the duration of the consultations will be registered. All participating clinicians and their patients will receive information about the study and complete an informed consent form beforehand.
This trial was retrospectively registered on August 03, 2021. Approval for the study was obtained from the ethical review board (medical research ethics committee Delft and Leiden, the Netherlands [N20.170]). Recruitment and data collection procedures are ongoing and are expected to be completed by July 2022; we plan to complete data analyses by December 2022. As of February 2022, a total of 12 hospitals have been recruited to participate in the study, and 30 clinicians have started the SDM training program.
This theory-based and blended approach will increase our knowledge of effective and feasible training methods for clinicians in the field of SDM. The intervention will be tailored to the context of individual clinicians and will target the knowledge, attitude, and skills of clinicians. The patients will also be involved in the design and implementation of the study.
Netherlands Trial Registry NL9647; https://www.trialregister.nl/trial/9647.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/35543.
共同决策(SDM)在肿瘤学中尤为重要,因为许多治疗都伴有严重的副作用,且治疗决策涉及利弊权衡。然而,在肿瘤护理中实施共同决策具有挑战性,临床医生表示在实际工作场所难以应用共同决策。众所周知,培训临床医生是提高共同决策水平的有效方法,但被认为耗时较长。
本研究旨在探讨采用刻意练习概念的个体共同决策培训项目的有效性。
这项多中心、单盲随机临床试验将在12家荷兰医院进行。邀请参与肿瘤患者决策的临床医生参与研究,并将其分配至对照组或干预组。所有临床医生将记录与3名不同肿瘤患者的3个决策过程。干预组的临床医生将接受以下共同决策干预:完成电子学习、反思反馈报告、进行自我评估并确定1至3个个人学习问题,以及参加面对面辅导。对照组的临床医生在研究结束前不接受共同决策干预。主要结局将是临床医生让患者参与决策过程的程度,使用“观察患者参与度-5”工具进行评分。作为次要结局,患者将对其在决策过程中的参与感进行评分,并记录会诊时长。所有参与研究的临床医生及其患者将提前收到有关研究的信息并填写知情同意书。
该试验于2021年8月3日进行回顾性注册。研究获得了伦理审查委员会(荷兰代尔夫特和莱顿医学研究伦理委员会 [N20.170])的批准。招募和数据收集程序正在进行中,预计于2022年7月完成;我们计划于2022年12月完成数据分析。截至2022年2月,共有12家医院被招募参与研究,30名临床医生已开始共同决策培训项目。
这种基于理论的混合方法将增加我们对肿瘤学领域临床医生有效且可行的培训方法的了解。该干预将根据个体临床医生的情况进行调整,并针对临床医生的知识、态度和技能。患者也将参与研究的设计和实施。
荷兰试验注册中心NL9647;https://www.trialregister.nl/trial/9647。
国际注册报告识别码(IRRID):DERR1-10.2196/35543。